Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events

Michele B. Kaufman, PharmD, BCGP  |  October 28, 2015

The FDA is asking for more safety analysis before approving tofacitinib to treat psoriasis. Also, adalimumab and etanercept received the greatest number of adverse and serious adverse events reported to the FDA in 2014…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabadverse eventsAnti-TNFetanerceptFDAFood and Drug AdministrationInstitute for Safe Medication Practicesplaque psoriasisTofacitinibtofacitinib citrate

Dr. Yokoyama, MD, with Jennifer Laurent

Interdisciplinary Collaboration at Wash U Advances Understanding of Immunology, Rheumatology

Gretchen Henkel  |  October 14, 2015

In June 2014, 10 members of a church group returned to St. Louis from Haiti, where they had contracted chikungunya virus (CHIKV), a mosquito-transmitted alphavirus previously unknown in the Western hemisphere that produces inflammatory arthritis symptoms. Because CHIKV-related arthritis mimics seronegative RA, a group of clinicians, immunologists, virologists and geneticists at the Washington University in…

Filed under:ConditionsOther Rheumatic ConditionsProfessional TopicsResearch Rheum Tagged with:CHIKVclinical trialscontracted chikungunya virusImmunologyoutcomeResearchrheumatology

Dual-Trained Rheumatologists Take Multidisciplinary Approach to Their Patients

Gretchen Henkel  |  October 14, 2015

Co-morbidities in patients with rheumatoid arthritis and related autoimmune diseases often warrant a multidisciplinary approach to treatment. When it comes to inflammatory and fibrotic lung conditions in these patients, collaboration between pulmonary/critical care specialists and rheumatologists is essential, say two rheumatologists recently interviewed by The Rheumatologist. Both followed their rheumatology fellowship training with additional fellowships…

Filed under:Career DevelopmentConditionsProfessional TopicsRheumatoid Arthritis Tagged with:ClinicalDiagnosislung disorderpatient careRARheumatoid arthritisrheumatologistrhuematologyTreatment

FOCIS 2015: Metabolism May Affect Immune System’s Reaction to Disease

Catherine Kolonko  |  October 13, 2015

How the immune system reacts to potential harm, such as lack of oxygen and inflammation, depends greatly on the human body’s metabolic processes and pathways, according to speakers at FOCIS 2015 in San Diego this past June. During a session devoted to metabolism and the immune system, researchers talked about recent studies that shed light…

Filed under:ConditionsMeeting Reports Tagged with:ClinicalDiseaseImmune Systemmetabolismoutcomepatient care

Case Report: Interstitial Lung Disease with Positive ANCA Test

Sara Tedeschi, MD  |  October 13, 2015

“Worst of all is the pain in my calves,” she said. “It feels like burning deep inside.” So began my first encounter with a 69-year-old woman who was referred to rheumatology clinic for evaluation of two months of constitutional symptoms and a positive ANCA test, which had been ordered by her primary care doctor. Her…

Filed under:Conditions Tagged with:ANCA patient careClinicalDiagnosisILDInterstitial Lung Diseaseoutcome

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  October 13, 2015

Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

Filed under:Conditions Tagged with:ClinicalOsteonecrosispatient carerheumatologyrhuematologist

Transatlantic Divide: How U.S. Pays Three Times More for Drugs

Reuters  |  October 13, 2015

LONDON (Reuters)—U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters. The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such…

Filed under:Drug Updates Tagged with:costsdrugpharmaceutical company

Immunotherapy May Be Effective for Some Patients with Autoimmune Cerebellar Ataxia

Will Boggs, MD  |  October 7, 2015

NEW YORK (Reuters Health)—Immunotherapy appears to yield neurological improvements in some patients with autoimmune cerebellar ataxia, especially those with nonparaneoplastic disorders, researchers report. “I was surprised that so many patients responded to immunotherapy (steroids, intravenous immunoglobulin (IVIg), and plasma exchange) and remained ambulatory,” Dr. Andrew McKeon from Mayo Clinic in Rochester, Minn., told Reuters Health…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Autoimmune Cerebellar AtaxiaAutoimmune diseaseCorticosteroidsimmunoglobulinimmunotherapyNeurologyrituximab

Biotechs Extend Selloff as Pricing Concerns Intensify

Caroline Valetkevitch & Bill Berkrot  |  October 7, 2015

NEW YORK (Reuters)—U.S. biotech shares extended their recent downward spiral on Tuesday as concerns about drug pricing continued to plague the sector while disappointing news from Illumina and other companies added to selling pressure. The Nasdaq Biotechnology index, down 4%, has now fallen about 17% since just before Hillary Clinton, front-runner to be the Democratic nominee…

Filed under:Drug Updates

Doctors Often Uncomfortable Soliciting Donations for Patients

Kathryn Doyle  |  October 3, 2015

NEW YORK (Reuters Health)—Many doctors are asked to seek donations from grateful patients after successful cancer treatment, but most physicians are uncomfortable with this idea and feel a conflict of interest, according to a new study. “There are ethical ways of seeking donations from patients who have the means and want to give back,” Dr….

Filed under:Practice SupportProfessional Topics Tagged with:FundraisingPhilanthropyphysician

  • « Previous Page
  • 1
  • …
  • 58
  • 59
  • 60
  • 61
  • 62
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences